Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 6/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473214 | 1.00 | PRMT5 (0.42) | PRMT5WDR77PARP1RIPK1PARP2 | |
| SCHEMBL2603308 | 0.76 | PARP1 (0.43) | PRMT5WDR77PARP1PARP2CHRNB2 | |
| SCHEMBL22473352 | 0.76 | PRMT5 (0.45) | PRMT5WDR77RIPK1ADAM17CHRNB2 | |
| SCHEMBL22473538 | 0.76 | PRMT5 (0.45) | PRMT5WDR77PARP1RIPK1 | |
| SCHEMBL22473215 | 0.76 | PRMT5 (0.45) | PRMT5WDR77RIPK1ADAM17CHRNB2 | |
| SCHEMBL23492368 | 0.76 | PRMT5 (0.45) | PRMT5WDR77PARP1RIPK1 | |
| SCHEMBL22473380 | 0.75 | SCN9A (0.38) | PRMT5WDR77RIPK1 | |
| SCHEMBL23491281 | 0.73 | RIPK1 (0.34) | PARP1RIPK1 | |
| SCHEMBL12643795 | 0.71 | PARP1 (0.42) | PARP1PARP2CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL2603272 | 0.71 | PARP1 (0.42) | PARP1PARP2CHRNB2CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | PRMT5 92/4885WDR77 589/4885PARP1 1568/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | PRMT5 92/4885WDR77 589/4885PARP1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.